On August 16, 2018, at 07:00am CEST, Calliditas Therapeutics (“Calliditas”) will publish its interim report for the second quarter of 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 10:00am CEST. The event will be hosted by the company’s CEO and President, Renée Aguiar-Lucander, and CFO Fredrik Johansson. The presentation will be held in English.
Slides used in the presentation will be live on the company’s website during the call under Financial Reports and Presentations and will also be made available on www.calliditas.com after the call. To participate in the telephone conference, please use the dial-in details shown below:
SE: +46850556453
UK: +442030089811
A link to audio cast can be found on the Calliditas website under Financial Reports and Presentations or here: https://financialhearings.com/event/11398
The information was released for public disclosure on August 13, 2018, at 08.00 CET.
For further information, please contact:
- Mikael Widell, Head of Communications
- Email: mikael.widell@calliditas.com
- Telephone: +46 703 11 99 60
About Calliditas
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit www.calliditas.com for further information.